Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hofseth Biocare ASA ( (HOFBF) ) just unveiled an update.
Hofseth BioCare ASA has approved its 2025 financial statements and released its Annual and Sustainability Reports, underscoring its focus on sustainable, science-based nutrition and health products derived from salmon by-products. The company highlights an October 2025 share placement intended to raise NOK 158 million, a transaction delayed by technical and legal issues with the main investor but expected by the board to close in the second quarter of 2026, which would markedly strengthen the balance sheet and underpin ongoing growth initiatives.
The planned capital injection is strategically important for maintaining growth momentum, supporting both the core ingredient business and the development of therapeutics in its HBC Immunology spin-out. By reinforcing its financial position while advancing patented health solutions in areas such as iron metabolism, immune function, obesity-related mechanisms, and cancer, HBC aims to consolidate its niche in sustainable marine-based health products and enhance its long-term appeal to investors and partners.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian consumer and pet health company that upcycles side streams from the salmon industry into high-value nutritional ingredients for humans and animals. Its main products include ProGo bioactive peptides and collagen, OmeGo whole salmon oil, and CalGo/NT-II salmon bone powder, all supported by scientific research, patents, and a growing biotech spin-out focused on oncology and respiratory therapeutics.
Average Trading Volume: 125,921
Current Market Cap: NOK614.6M
For detailed information about HOFBF stock, go to TipRanks’ Stock Analysis page.